| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Total operating revenue | 136,564 | 119,802 | ||
| Direct costs-Health Care Patient Service | 54,572 | 51,150 | ||
| Direct costs-Dispensary Revenue | 63,072 | 51,086 | ||
| Direct costs-Clinical Research Trials And Other Revenue | 0 | 65 | ||
| Selling, general and administrative expense | 25,251 | 26,907 | ||
| Depreciation and amortization | 1,723 | 1,805 | ||
| Total operating expenses | 144,618 | 131,013 | ||
| Loss from operations | -8,054 | -11,211 | ||
| Interest expense, net | 1,920 | 1,870 | ||
| Change in fair value of derivative warrant liabilities | 150 | 53 | ||
| Change in fair value of conversion option derivative liabilities | -5,977 | -3,987 | ||
| Other, net | -403 | -19 | ||
| Total other non-operating loss | -8,450 | -5,929 | ||
| Loss before provision for income taxes | -16,504 | -17,140 | ||
| Income tax benefit | 0 | -131 | ||
| Net loss | -16,504 | -17,009 | ||
| Basic (in dollars per share) | -0.14 | -0.15 | ||
| Basic (in shares) | 97,474,797 | 93,203,665 | ||
| Diluted (in dollars per share) | -0.14 | -0.15 | ||
| Diluted (in shares) | 97,474,797 | 93,203,665 | ||
Oncology Institute, Inc. (TOIIW)
Oncology Institute, Inc. (TOIIW)